Impact Biomedical (IBO) EBIT Margin (2022 - 2026)
Impact Biomedical (IBO) posted EBIT Margin of 32700.0% for Q1 2026, down 520.89% on a QoQ basis from 5266.67% in Q3 2025.
Impact Biomedical (IBO) EBIT Margin (2022 - 2026) Analysis & Trends
Impact Biomedical's EBIT Margin history runs 3 years deep, the most recent figure standing at 32700.0% for Q1 2026.
- Quarterly EBIT Margin changed N/A year-over-year to 32700.0% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 16875.0% (changed N/A YoY) and the FY2022 annual result came in at 6808.0%, changed N/A from the prior year.
- EBIT Margin was 32700.0% for Q1 2026 at Impact Biomedical, down from 5266.67% in the prior quarter.
- Across five years, EBIT Margin topped out at 1500.0% in Q2 2022 and bottomed at 32700.0% in Q1 2026.
- A 3-year average of 13984.52% and a median of 10869.05% in 2025 frame the typical range for EBIT Margin.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Impact Biomedical | 47.44 Mn | 50.67 Mn | - | -32,700.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -32,700.00% |
| Sep 30, 2025 | -5,266.67% |
| Jun 30, 2025 | -16,471.43% |
| Jun 30, 2022 | -1,500.00% |